In a landmark medical breakthrough, Russia has developed Enteromix the world’s first personalized mRNA-based cancer vaccine showing 100% efficacy in early clinical trials. Announced by the Federal Medical and Biological Agency (FMBA) and unveiled at the St. Petersburg International Economic Forum 2025, the vaccine is now awaiting final regulatory approval. If cleared, it will mark a transformative leap in precision oncology, offering tailored treatment based on each patient’s unique tumor genetics.
Enteromix was developed jointly by Russia’s National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology. Unlike preventive vaccines, Enteromix is therapeutic designed for patients already diagnosed with cancer. It works by extracting a sample of the patient’s tumor, sequencing its RNA, and creating a customized mRNA vaccine that instructs the body to produce proteins mimicking the cancer cells. The immune system then recognizes these as threats and deploys T-cells to hunt down and destroy malignant cells without the debilitating side effects of chemotherapy or radiation.
Initial Phase I trials began in June 2025 with 48 colorectal cancer patients. Results showed tumor reduction of 60–80% in some cases, with complete elimination in early-stage patients. No serious side effects were reported, even after repeated doses. FMBA chief Veronika Skvortsova confirmed the vaccine is “personalized for each patient,” making it a true pioneer in individualized cancer therapy.
Unlike traditional oncology treatments, personalized mRNA vaccines are engineered using a patient’s unique tumor genomic profile. This approach enables highly targeted immune activation against neoantigens — potentially improving therapeutic efficacy while minimizing systemic toxicity.
The emergence of personalized mRNA cancer vaccines such as EnteroMix signals accelerating innovation across both oncology immunotherapy and mRNA platform technologies.
BIS Research offers dedicated market intelligence across both layers of this opportunity — enabling stakeholders to evaluate commercial potential, competitive positioning, and long-term growth outlook.
Criteria | Global Neoantigen Cancer Vaccine Market Report | mRNA Vaccines & Therapeutics Market Report |
|---|---|---|
Primary Focus | Personalized & neoantigen-based cancer vaccines | Broad mRNA applications across diseases |
Technology Scope | Highly oncology-focused | Infectious diseases, oncology, rare diseases, therapeutics |
Relevance to EnteroMix News | Directly aligned with personalized cancer vaccines | Aligned at platform and delivery technology level |
Strategic Use Case | Oncology pipeline strategy, competitive benchmarking | Platform expansion, manufacturing & delivery scaling |
Ideal For | Oncology biotech firms, pharma companies and oncology investors | mRNA platform companies, CDMOs, delivery tech players |
Type of Insights | Clinical pipeline tracking, regional forecasts, regulatory outlook | Market sizing, CAGR forecasts, manufacturing trends |
Download Neoantigen Cancer Vaccine Report ToC
Download mRNA Vaccine and Therapeutics Report ToC
Globally, Russia isn’t alone BioNTech, Moderna, and CureVac are racing ahead with their own mRNA vaccines, some nearing regulatory approval by 2026. The UK’s NHS has even launched a national trial aiming to treat thousands by 2030.
For India, access remains uncertain. While no official timeline exists, any rollout would require approval from India’s Drug Controller and local trials. In Russia, one dose costs approximately 2.5 lakh, but is provided free to citizens. If adopted under India’s National Health Mission, costs could be subsidized or eliminated.
With 10 million cancer deaths annually worldwide, Enteromix offers real hope not as a guaranteed cure, but as a powerful new tool in the evolving arsenal against cance
